Claims for Patent: 12,605,365

Summary for Patent: 12,605,365

Title:	Losartan liquid formulations and methods of use
Abstract:	The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.
Inventor(s):	Bhavya Teja KOLLA, Rahul Surana, Suketu Sanghvi, Jigar BHATT
Assignee:	Meds Merger Sub Ii LLC , Scienture LLC
Application Number:	US18/061,819
Patent Claims:	1. A method of treating hypertension comprising administering to a human in need thereof an oral pharmaceutical composition comprising: about 10 mg/mL of losartan or a pharmaceutically acceptable salt thereof, a suspending agent selected from the group consisting of hydroxyethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium carboxymethylcellulose, xanthan gum, acacia, an alginate, and guar gum, or a combination thereof; a pH modifying agent; a preservative; and a solubilizer, wherein the pharmaceutical composition is a liquid suspension, and wherein the liquid suspension has a pH of about 7. 2. The method of claim 1, wherein the oral pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of an emulsifying agent, an antioxidant, a chelating agent, a surfactant or wetting agent, a sweetener, a stabilizer, a flavoring agent, and a colorant. 3. The method of claim 1, wherein the oral pharmaceutical composition further comprises crystallization inhibitor. 4. The method of claim 1, wherein the pharmaceutically acceptable salt is losartan potassium. 5. The method of claim 1, wherein the oral pharmaceutical composition further comprises PEG 400, propylene glycol, or both. 6. The method of claim 1, wherein the preservative comprises methyl paraben, propyl paraben, or both. 7. The method of claim 1, wherein the pH modifying agent comprises sodium phosphate monobasic, sodium phosphate dibasic, or both. 8. The method of claim 1, wherein the flavoring agent comprises a mint flavor. 9. The method of claim 1, wherein the suspending agent comprises xanthan gum. 10. The method of claim 1, wherein the oral pharmaceutical composition further comprises an anti-foaming agent. 11. A method of treating nephropathy comprising administering to a human in need thereof an oral pharmaceutical composition comprising: about 10 mg/mL of losartan or a pharmaceutically acceptable salt thereof, a suspending agent selected from the group consisting of hydroxyethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium carboxymethylcellulose, xanthan gum, acacia, an alginate, and guar gum, or a combination thereof; a pH modifying agent; a preservative; and a solubilizer, wherein the pharmaceutical composition is a liquid suspension, and wherein the liquid suspension has a pH of about 7. 12. The method of claim 11, wherein the oral pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of an emulsifying agent, an antioxidant, a chelating agent, a surfactant or wetting agent, a sweetener, a stabilizer, a flavoring agent, and a colorant. 13. The method of claim 11, wherein the suspending agent comprises xanthan gum. 14. The method of claim 11, wherein the pharmaceutically acceptable salt is losartan potassium. 15. The method of claim 11, wherein the oral pharmaceutical composition further comprises PEG 400, propylene glycol, or both. 16. The method of claim 11, wherein the preservative comprises methyl paraben, propyl paraben, or both. 17. The method of claim 11, wherein the pH modifying agent comprises sodium phosphate monobasic, sodium phosphate dibasic, or both. 18. The method of claim 11, wherein the oral pharmaceutical composition further comprises a crystallization inhibitor. 19. The method of claim 11, wherein the oral pharmaceutical composition further comprises an anti-foaming agent. 20. A method of treating hypertension or diabetic nephropathy comprising administering to a human in need thereof an oral pharmaceutical composition comprising: about 10 mg/mL of losartan potassium, a suspending agent selected from the group consisting of hydroxyethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium carboxymethylcellulose, xanthan gum, acacia, an alginate, and guar gum, or a combination thereof; a pH modifying agent; a preservative; a solubilizer; an emulsifying agent; and a crystallization inhibitor, wherein the pharmaceutical composition is a liquid suspension, and wherein the liquid suspension has a pH of about 7.